While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past three years have been challenging for Pfizer (NYSE: PFE). Although Pfizer ...

Some things are unsaid though. The forced marriage with AKQA has damaged both brands. Unlike David, INGO and NCA Grey isn’t a relatively recent creative invention it’s one of adland’s more venerable ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Pfizer's CEO, Albert Bourla, said tariffs are preventing the company from making "tremendous investments" in the US. Leigh Vogel/Getty Images for Concordia Summit 2025-04-30T04:30:53Z ...

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.. Analysts expect the New York-based company to report quarterly earnings at 68 ...

As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. CNN values your feedback 1.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury that resolved after the ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity.